{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:00:45Z","timestamp":1790362845961,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81373454"],"award-info":[{"award-number":["81373454"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Acinetobacter baumannii<\/jats:italic> is a common pathogen of nosocomial infection, and its ability to form biofilms further contributes to its virulence and multidrug resistance, posing a great threat to global public health. In this study, we investigated the inhibitory effects of five biofilm inhibitors (BFIs) (zinc lactate, stannous fluoride, furanone, azithromycin, and rifampicin) on biofilm formation of nine extensively drug-resistant <jats:italic>A. baumannii<\/jats:italic> (XDRAB), and assessed the synergistic antibacterial effects of these BFIs when combined with one of four conventional anti-<jats:italic>A. baumannii<\/jats:italic> antibiotics (imipenem, meropenem, tigecycline, and polymyxin B). Each of the five BFIs tested was found to be able to significantly inhibit biofilm formation of all the clinical isolates tested under sub-minimal inhibitory concentrations. Then, we observed synergistic effects (in 22%, 56% and 11% of the isolates) and additive effects (56%, 44% and 44%) when zinc lactate, stannous fluoride and furanone were combined with tigecycline, respectively. When zinc lactate and stannous fluoride were each used with a carbapenem (imipenem or meropenem), in 33% and 56\u201367% of the isolates, they showed synergistic and additive effects, respectively. Additivity in\u2009&gt;\u200950% of the isolates was detected when rifampicin was combined with imipenem, meropenem, tigecycline, or polymyxin B; and a 100% additivity was noted with azithromycin-polymyxin B combination. However, antagonism and indifference were noted for polymyxin B in its combination with zinc lactate and stannous fluoride, respectively. In conclusion, five BFIs in combination with four antibacterial drugs showed different degrees of in vitro synergistic and additive antibacterial effects against XDRAB.<\/jats:p>","DOI":"10.1038\/s41598-020-75218-y","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T10:03:14Z","timestamp":1603360994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["In vitro activity of biofilm inhibitors in combination with antibacterial drugs against extensively drug-resistant Acinetobacter baumannii"],"prefix":"10.1038","volume":"10","author":[{"given":"Qin","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baodong","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"75218_CR1","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1128\/CMR.00058-07","volume":"21","author":"AY Peleg","year":"2008","unstructured":"Peleg, A. Y., Seifert, H. & Paterson, D. L. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21, 538\u2013582. https:\/\/doi.org\/10.1128\/CMR.00058-07 (2008).","journal-title":"Clin. Microbiol. Rev."},{"key":"75218_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/978-3-319-39658-3_13","volume-title":"Acinetobacter in Efflux-Mediated Antimicrobial Resistance in Bacteria: Mechanisms, Regulation and Clinical Implications","author":"B-D Ling","year":"2016","unstructured":"Ling, B.-D., Zhang, L. & Li, X.-Z. Antimicrobial resistance and drug efflux pumps. In Acinetobacter in Efflux-Mediated Antimicrobial Resistance in Bacteria: Mechanisms, Regulation and Clinical Implications (eds Li, X.-Z. et al.) 329\u2013358 (Springer, Berlin, 2016)."},{"key":"75218_CR3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 18, 318\u2013327. https:\/\/doi.org\/10.1016\/S1473-3099(17)30753-3 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"75218_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.coph.2013.07.004","volume":"13","author":"MS Blackledge","year":"2013","unstructured":"Blackledge, M. S., Worthington, R. J. & Melander, C. Biologically inspired strategies for combating bacterial biofilms. Curr. .Opin Pharmacol. 13, 699\u2013706. https:\/\/doi.org\/10.1016\/j.coph.2013.07.004 (2013).","journal-title":"Curr. .Opin Pharmacol."},{"key":"75218_CR5","doi-asserted-by":"publisher","first-page":"DC08-10","DOI":"10.7860\/JCDR\/2015\/11014.5398","volume":"9","author":"GK Badave","year":"2015","unstructured":"Badave, G. K. & Kulkarni, D. Biofilm producing multidrug resistant Acinetobacter baumannii: an emerging challenge. J. Clin. Diagn. Res. 9, DC08-10. https:\/\/doi.org\/10.7860\/JCDR\/2015\/11014.5398 (2015).","journal-title":"J. Clin. Diagn. Res."},{"key":"75218_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1471-2334-13-47","volume":"13","author":"CJ Sanchez Jr","year":"2013","unstructured":"Sanchez, C. J. Jr. et al. Biofilm formation by clinical isolates and the implications in chronic infections. BMC Infect. Dis. 13, 47. https:\/\/doi.org\/10.1186\/1471-2334-13-47 (2013).","journal-title":"BMC Infect. Dis."},{"key":"75218_CR7","doi-asserted-by":"publisher","first-page":"ofaa161","DOI":"10.1093\/ofid\/ofaa161","volume":"7","author":"O Henig","year":"2020","unstructured":"Henig, O. et al. The impact of multidrug-resistant organisms on outcomes in patients with diabetic foot infections. Open Forum Infect. Dis. 7, ofaa161. https:\/\/doi.org\/10.1093\/ofid\/ofaa161 (2020).","journal-title":"Open Forum Infect. Dis."},{"key":"75218_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1128\/cmr.15.2.167-193.2002","volume":"15","author":"RM Donlan","year":"2002","unstructured":"Donlan, R. M. & Costerton, J. W. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15, 167\u2013193. https:\/\/doi.org\/10.1128\/cmr.15.2.167-193.2002 (2002).","journal-title":"Clin. Microbiol. Rev."},{"key":"75218_CR9","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/femsre\/fux010","volume":"41","author":"CW Hall","year":"2017","unstructured":"Hall, C. W. & Mah, T. F. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. FEMS Microbiol. Rev. 41, 276\u2013301. https:\/\/doi.org\/10.1093\/femsre\/fux010 (2017).","journal-title":"FEMS Microbiol. Rev."},{"key":"75218_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.02508-16","author":"A Algburi","year":"2017","unstructured":"Algburi, A., Comito, N., Kashtanov, D., Dicks, L. M. T. & Chikindas, M. L. Control of biofilm formation: antibiotics and beyond. Appl. Environ. Microbiol. https:\/\/doi.org\/10.1128\/AEM.02508-16 (2017).","journal-title":"Appl. Environ. Microbiol."},{"key":"75218_CR11","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1097\/CCM.0000000000001029","volume":"43","author":"B Spellberg","year":"2015","unstructured":"Spellberg, B. & Bonomo, R. A. Combination therapy for extreme drug-resistant Acinetobacter baumannii: ready for prime time?. Crit .Care Med. 43, 1332\u20131334. https:\/\/doi.org\/10.1097\/CCM.0000000000001029 (2015).","journal-title":"Crit .Care Med."},{"key":"75218_CR12","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1099\/jmm.0.024372-0","volume":"59","author":"RG Ledder","year":"2010","unstructured":"Ledder, R. G., Sreenivasan, P. K., DeVizio, W. & McBain, A. J. Evaluation of the specificity and effectiveness of selected oral hygiene actives in salivary biofilm microcosms. J. Med. Microbiol. 59, 1462\u20131468. https:\/\/doi.org\/10.1099\/jmm.0.024372-0 (2010).","journal-title":"J. Med. Microbiol."},{"key":"75218_CR13","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.13345\/j.cjb.170141","volume":"33","author":"S Yu","year":"2017","unstructured":"Yu, S., Zhang, M. & Ma, L. Anti-biofilm effects of Zn lactate\u00b73H2O and SnF2 on Pseudomonas aeruginosa, Acinetobacter baumannii and Streptococcus mutans. Chin. J. Biotechnol. 33, 1478\u20131488. https:\/\/doi.org\/10.13345\/j.cjb.170141 (2017).","journal-title":"Chin. J. Biotechnol."},{"key":"75218_CR14","doi-asserted-by":"publisher","first-page":"647","DOI":"10.4155\/fmc.15.7","volume":"7","author":"N Rabin","year":"2015","unstructured":"Rabin, N. et al. Agents that inhibit bacterial biofilm formation. Future Med. Chem. 7, 647\u2013671. https:\/\/doi.org\/10.4155\/fmc.15.7 (2015).","journal-title":"Future Med. Chem."},{"key":"75218_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3947\/ic.2015.47.1.27","volume":"47","author":"JY Song","year":"2015","unstructured":"Song, J. Y., Cheong, H. J., Noh, J. Y. & Kim, W. J. In vitro comparison of anti-biofilm effects against carbapenem-resistant Acinetobacter baumannii: imipenem, colistin, tigecycline, rifampicin and combinations. Infect. Chemother. 47, 27\u201332. https:\/\/doi.org\/10.3947\/ic.2015.47.1.27 (2015).","journal-title":"Infect. Chemother."},{"key":"75218_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41586-018-0278-9","volume":"559","author":"AR Brochado","year":"2018","unstructured":"Brochado, A. R. et al. Species-specific activity of antibacterial drug combinations. Nature 559, 259\u2013263. https:\/\/doi.org\/10.1038\/s41586-018-0278-9 (2018).","journal-title":"Nature"},{"key":"75218_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-020-03882-z","author":"NM Seleem","year":"2020","unstructured":"Seleem, N. M., Abd El Latif, H. K., Shaldam, M. A. & El-Ganiny, A. Drugs with new lease of life as quorum sensing inhibitors: for combating MDR Acinetobacter baumannii infections. Eur. J. Clin. Microbiol. Infect. Dis. https:\/\/doi.org\/10.1007\/s10096-020-03882-z (2020).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"75218_CR18","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 30th ed. CLSI supplement M100. (Wayne, Pennsylvania: Clinical and Laboratory Standards Institute, 2020)."},{"key":"75218_CR19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos, A. P. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18, 268\u2013281. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03570.x (2012).","journal-title":"Clin. Microbiol. Infect."},{"key":"75218_CR20","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.1128\/AAC.00839-16","volume":"60","author":"S Bae","year":"2016","unstructured":"Bae, S. et al. In vitro synergistic activity of antimicrobial agents in combination against clinical isolates of colistin-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 60, 6774\u20136779. https:\/\/doi.org\/10.1128\/AAC.00839-16 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"75218_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/lam.12789","volume":"65","author":"T Pimchan","year":"2017","unstructured":"Pimchan, T., Maensiri, D. & Eumkeb, G. Synergy and mechanism of action of alpha-mangostin and ceftazidime against ceftazidime-resistant Acinetobacter baumannii. Lett. Appl. Microbiol. 65, 285\u2013291. https:\/\/doi.org\/10.1111\/lam.12789 (2017).","journal-title":"Lett. Appl. Microbiol."},{"key":"75218_CR22","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.2147\/IDR.S169894","volume":"11","author":"EC Eze","year":"2018","unstructured":"Eze, E. C., Chenia, H. Y. & El Zowalaty, M. E. Acinetobacter baumannii biofilms: effects of physicochemical factors, virulence, antibiotic resistance determinants, gene regulation, and future antimicrobial treatments. Infect. Drug Resist. 11, 2277\u20132299. https:\/\/doi.org\/10.2147\/IDR.S169894 (2018).","journal-title":"Infect. Drug Resist."},{"key":"75218_CR23","doi-asserted-by":"publisher","first-page":"110319","DOI":"10.1016\/j.msec.2019.110319","volume":"108","author":"PP Mahamuni-Badiger","year":"2020","unstructured":"Mahamuni-Badiger, P. P. et al. Biofilm formation to inhibition: role of zinc oxide-based nanoparticles. Mater. Sci. Eng. C Mater. Biol. Appl. 108, 110319. https:\/\/doi.org\/10.1016\/j.msec.2019.110319 (2020).","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"75218_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3389\/fcimb.2018.00310","volume":"8","author":"C Mayer","year":"2018","unstructured":"Mayer, C. et al. Multiple quorum quenching enzymes are active in the nosocomial pathogen Acinetobacter baumannii ATCC17978. Front. Cell Infect. Microbiol. 8, 310. https:\/\/doi.org\/10.3389\/fcimb.2018.00310 (2018).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"75218_CR25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fmicb.2014.00178","volume":"5","author":"F Imperi","year":"2014","unstructured":"Imperi, F., Leoni, L. & Visca, P. Antivirulence activity of azithromycin in Pseudomonas aeruginosa. Front. Microbiol. 5, 178. https:\/\/doi.org\/10.3389\/fmicb.2014.00178 (2014).","journal-title":"Front. Microbiol."},{"key":"75218_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/1120009X.2017.1378835","volume":"30","author":"M Bogdan","year":"2018","unstructured":"Bogdan, M. et al. In vitro effect of subminimal inhibitory concentrations of antibiotics on the biofilm formation ability of Acinetobacter baumannii clinical isolates. J. Chemother. 30, 16\u201324. https:\/\/doi.org\/10.1080\/1120009X.2017.1378835 (2018).","journal-title":"J. Chemother."},{"key":"75218_CR27","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s10096-016-2736-3","volume":"35","author":"H Nordqvist","year":"2016","unstructured":"Nordqvist, H., Nilsson, L. E. & Claesson, C. Mutant prevention concentration of colistin alone and in combination with rifampicin for multidrug-resistant Acinetobacter baumannii. Eur. J. Clin. Microbiol. Infect. Dis. 35, 1845\u20131850. https:\/\/doi.org\/10.1007\/s10096-016-2736-3 (2016).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"75218_CR28","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3109\/00365548.2013.865141","volume":"46","author":"P Majewski","year":"2014","unstructured":"Majewski, P. et al. In vitro activity of rifampicin alone and in combination with imipenem against multidrug-resistant Acinetobacter baumannii harboring the blaOXA-72 resistance gene. Scand. J. Infect. Dis. 46, 260\u2013264. https:\/\/doi.org\/10.3109\/00365548.2013.865141 (2014).","journal-title":"Scand. J. Infect. Dis."},{"key":"75218_CR29","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1128\/AAC.04089-14","volume":"59","author":"Y Bai","year":"2015","unstructured":"Bai, Y. et al. In vitro activities of combinations of rifampin with other antimicrobials against multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 59, 1466\u20131471. https:\/\/doi.org\/10.1128\/AAC.04089-14 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"75218_CR30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1476-0711-5-10","volume":"5","author":"DW Wareham","year":"2006","unstructured":"Wareham, D. W. & Bean, D. C. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann. Clin. Microbiol. Antimicrob. 5, 10. https:\/\/doi.org\/10.1186\/1476-0711-5-10 (2006).","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"75218_CR31","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1128\/AAC.00367-09","volume":"54","author":"ME Pachon-Ibanez","year":"2010","unstructured":"Pachon-Ibanez, M. E. et al. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 54, 1165\u20131172. https:\/\/doi.org\/10.1128\/AAC.00367-09 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"75218_CR32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1128\/MMBR.56.3.395-411.1992","volume":"56","author":"M Vaara","year":"1992","unstructured":"Vaara, M. Agents that increase the permeability of the outer membrane. Microbiol. Rev. 56, 395\u2013411 (1992).","journal-title":"Microbiol. Rev."},{"key":"75218_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ijantimicag.2016.06.023","volume":"48","author":"S Baron","year":"2016","unstructured":"Baron, S., Hadjadj, L., Rolain, J. M. & Olaitan, A. O. Molecular mechanisms of polymyxin resistance: knowns and unknowns. Int. J. Antimicrob. Agents 48, 583\u2013591. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.06.023 (2016).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"75218_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1556\/AMicr.57.2010.3.8","volume":"57","author":"B Kadar","year":"2010","unstructured":"Kadar, B. et al. In vitro activity of clarithromycin in combination with other antimicrobial agents against biofilm-forming Pseudomonas aeruginosa strains. Acta Microbiol. Immunol. Hung. 57, 235\u2013245. https:\/\/doi.org\/10.1556\/AMicr.57.2010.3.8 (2010).","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"75218_CR35","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1128\/CMR.00117-14","volume":"28","author":"X-Z Li","year":"2015","unstructured":"Li, X.-Z., Plesiat, P. & Nikaido, H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin. Microbiol. Rev. 28, 337\u2013418. https:\/\/doi.org\/10.1128\/CMR.00117-14 (2015).","journal-title":"Clin. Microbiol. Rev."},{"key":"75218_CR36","first-page":"134","volume":"25","author":"JA Lepe","year":"2012","unstructured":"Lepe, J. A., Garcia-Cabrera, E., Gil-Navarro, M. V. & Aznar, J. Rifampin breakpoint for Acinetobacter baumannii based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. Rev. Esp. Quimioter. 25, 134\u2013138 (2012).","journal-title":"Rev. Esp. Quimioter."},{"key":"75218_CR37","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s40265-014-0267-8","volume":"74","author":"JA Viehman","year":"2014","unstructured":"Viehman, J. A., Nguyen, M. H. & Doi, Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs 74, 1315\u20131333. https:\/\/doi.org\/10.1007\/s40265-014-0267-8 (2014).","journal-title":"Drugs"},{"key":"75218_CR38","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1017\/S095026881200194X","volume":"141","author":"H Aydemir","year":"2013","unstructured":"Aydemir, H. et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol. Infect. 141, 1214\u20131222. https:\/\/doi.org\/10.1017\/S095026881200194X (2013).","journal-title":"Epidemiol. Infect."},{"key":"75218_CR39","doi-asserted-by":"publisher","first-page":"e346","DOI":"10.4317\/jced.55418","volume":"11","author":"P Srisilapanan","year":"2019","unstructured":"Srisilapanan, P., Roseman, J. & Likitsatian, T. Clinical effect of toothpaste and mouth rinse containing zinc lactate on oral malodor reduction. J. Clin. Exp. Dent. 11, e346\u2013e352. https:\/\/doi.org\/10.4317\/jced.55418 (2019).","journal-title":"J. Clin. Exp. Dent."},{"key":"75218_CR40","doi-asserted-by":"publisher","first-page":"CD00284","DOI":"10.1002\/14651858.CD002284.pub2","volume":"7","author":"VC Marinho","year":"2016","unstructured":"Marinho, V. C., Chong, L. Y., Worthington, H. V. & Walsh, T. Fluoride mouthrinses for preventing dental caries in children and adolescents. Cochrane Database Syst. Rev. 7, CD00284. https:\/\/doi.org\/10.1002\/14651858.CD002284.pub2 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"75218_CR41","doi-asserted-by":"publisher","first-page":"74","DOI":"10.7205\/milmed.173.1.74","volume":"173","author":"SC Davis","year":"2008","unstructured":"Davis, S. C., Pissani, F. & Montero, R. B. Effects of commonly used topical antimicrobial agents on Acinetobacter baumannii: an in vitro study. Mil. Med. 173, 74\u201378. https:\/\/doi.org\/10.7205\/milmed.173.1.74 (2008).","journal-title":"Mil. Med."},{"key":"75218_CR42","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3389\/fmicb.2015.00910","volume":"6","author":"Y Chang","year":"2015","unstructured":"Chang, Y. et al. Characterization of carbapenem-resistant Acinetobacter baumannii isolates in a Chinese teaching hospital. Front. Microbiol. 6, 910. https:\/\/doi.org\/10.3389\/fmicb.2015.00910 (2015).","journal-title":"Front. Microbiol."},{"key":"75218_CR43","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.3389\/fmicb.2017.01836","volume":"8","author":"F Lin","year":"2017","unstructured":"Lin, F. et al. Molecular characterization of reduced susceptibility to biocides in clinical Isolates of Acinetobacter baumannii. Front. Microbiol. 8, 1836. https:\/\/doi.org\/10.3389\/fmicb.2017.01836 (2017).","journal-title":"Front. Microbiol."},{"key":"75218_CR44","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 28th ed. CLSI supplement M100. (Wayne, Pennsylvania: Clinical and Laboratory Standards Institute, 2018)."},{"key":"75218_CR45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3969\/j.issn.1674-2257.2017.02.001","volume":"12","author":"C Zhang","year":"2017","unstructured":"Zhang, C. et al. A study on the antibacterial effect of Chinese medicine plumbagin on tigecycline-resistant Acinetobacter baumannii. J. Chengdu Med. Coll. 12, 6\u201310. https:\/\/doi.org\/10.3969\/j.issn.1674-2257.2017.02.001 (2017).","journal-title":"J. Chengdu Med. Coll."},{"key":"75218_CR46","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1128\/JB.00389-11","volume":"193","author":"J Aranda","year":"2011","unstructured":"Aranda, J. et al. Acinetobacter baumannii RecA protein in repair of DNA damage, antimicrobial resistance, general stress response, and virulence. J. Bacteriol. 193, 3740\u20133747. https:\/\/doi.org\/10.1128\/JB.00389-11 (2011).","journal-title":"J. Bacteriol."},{"key":"75218_CR47","doi-asserted-by":"publisher","first-page":"e0162576","DOI":"10.1371\/journal.pone.0162576","volume":"11","author":"GN Selasi","year":"2016","unstructured":"Selasi, G. N. et al. Differences in biofilm mass, expression of biofilm-associated genes, and resistance to desiccation between epidemic and sporadic clones of carbapenem-resistant Acinetobacter baumannii sequence type 191. PLoS ONE 11, e0162576. https:\/\/doi.org\/10.1371\/journal.pone.0162576 (2016).","journal-title":"PLoS ONE"},{"key":"75218_CR48","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0732-8893(93)90087-n","volume":"16","author":"MH Hsieh","year":"1993","unstructured":"Hsieh, M. H., Yu, C. M., Yu, V. L. & Chow, J. W. Synergy assessed by checkerboard. A critical analysis. Diagn. Microbiol. Infect. Dis. 16, 343\u2013349. https:\/\/doi.org\/10.1016\/0732-8893(93)90087-n (1993).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"75218_CR49","doi-asserted-by":"publisher","first-page":"9819","DOI":"10.3390\/molecules16129819","volume":"16","author":"GY Zuo","year":"2011","unstructured":"Zuo, G. Y. et al. Synergistic antibacterial and antibiotic effects of bisbenzylisoquinoline alkaloids on clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). Molecules 16, 9819\u20139826. https:\/\/doi.org\/10.3390\/molecules16129819 (2011).","journal-title":"Molecules"},{"key":"75218_CR50","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1128\/JCM.00001-14","volume":"52","author":"D Marchaim","year":"2014","unstructured":"Marchaim, D. et al. Major variation in MICs of tigecycline in Gram-negative bacilli as a function of testing method. J. Clin. Microbiol. 52, 1617\u20131621. https:\/\/doi.org\/10.1128\/JCM.00001-14 (2014).","journal-title":"J. Clin. Microbiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75218-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75218-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75218-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T21:54:30Z","timestamp":1670363670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75218-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["75218"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-75218-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"assertion":[{"value":"30 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18097"}}